Episode Summary
Executive Summary: Peter Attia and Dr. Alan Snyderman argue that ApoB is the most clinically useful marker for atherosclerotic risk because it counts atherogenic particles, not just cholesterol mass. They critique 10-year risk calculators and LDL-C–centric guidelines for missing early disease, emphasize long-horizon prevention, discuss special cases like type III dyslipoproteinemia, and explain why CAC scoring and consensus guidelines have important blind spots.
Main Topics: ApoB as the causal driver of atherosclerosis (Priority: 5/5): Snyderman explains that atherosclerosis begins when ApoB-containing particles enter and become trapped in the arterial wall; cholesterol is the cargo, but particle number is the key causal metric. Why 10-year risk calculators fail (Priority: 5/5): The discussion argues that age-dominated 10-year risk tools delay prevention until disease is already advanced, missing the decades-long development of atherosclerosis and many premature events. LDL-C, non-HDL-C, and ApoB discordance (Priority: 5/5): They compare LDL-C, non-HDL-C, and ApoB, arguing that LDL-C is often calculated, non-HDL-C is better, but ApoB best captures atherogenic particle burden, especially when cholesterol content per particle varies. Special dyslipoproteinemias and diagnostic blind spots (Priority: 4/5): Type III dyslipoproteinemia is highlighted as a high-risk condition that can be missed without ApoB measurement, showing why particle-based assessment matters beyond routine lipid panels. Mendelian randomization and causality (Priority: 4/5): Snyderman uses Mendelian randomization to support ApoB as causal, while noting that HDL-C manipulation has failed to improve outcomes and that triglyceride associations often disappear after accounting for ApoB. Coronary artery calcium scoring: useful but limited (Priority: 4/5): CAC is presented as helpful for younger or uncertain patients, but a zero score does not rule out active disease or negate high ApoB risk; positive CAC in younger people is especially concerning. Guidelines, consensus, and resistance to change (Priority: 5/5): The conversation criticizes unanimous guideline processes for underweighting ApoB evidence, over-relying on LDL-C, and failing to incorporate cost, assay quality, and newer evidence adequately.
Key Arguments: ApoB is superior to LDL-C because every atherogenic particle carries one ApoB molecule, so ApoB directly reflects the number of particles that can enter and be retained in the arterial wall. Non-HDL-C is better than LDL-C, but ApoB is often better still because cholesterol content per particle varies widely; two people with the same LDL-C can have very different particle burdens and risk. 10-year risk calculators are structurally biased toward age and sex, which delays treatment until after atherosclerosis is already established; a 20- to 30-year horizon better matches disease biology. Many first cardiovascular events occur before age 60, so waiting for a high 10-year risk score misses the window for true prevention. Type III dyslipoproteinemia is a clinically important exception: patients can have high triglycerides and cholesterol with low ApoB, and this can be missed if ApoB is not measured. Mendelian randomization strengthens the causal case for ApoB by using fixed genetic variation to reduce confounding; HDL-C has not held up as a causal target in the same way. CAC scoring is useful for detecting advanced disease, especially in younger patients, but a zero score does not mean low long-term risk when ApoB is high. Guidelines lag because consensus processes can become overly unanimous and resistant to dissenting evidence, especially when they rely on simplified summaries rather than full scientific debate. ApoB testing is inexpensive and standardized, so cost is not a strong argument against its routine use. Statins work largely by lowering ApoB particle number, thereby reducing the number of particles that can enter and be trapped in the artery wall.
Data Points: Age threshold for guideline treatment: 55-60 years - Snyderman argues most 10-year risk tools trigger treatment too late, after disease has already progressed. Premature events before age 60: Almost half of all infarcts and strokes - Used to show why 10-year risk models miss a large share of clinically important disease. ApoB assay cost: $2 to $2.50 cash price - Used to rebut claims that ApoB is too expensive to measure routinely. ApoB standardization: Standardized in 1994 - Presented as evidence that ApoB is a reliable lab test. LDL-C calculation methods: At least 8 different methods - Illustrates that LDL-C is often estimated rather than directly measured and is method-dependent. Risk calculator example: 4.1% 10-year risk - Used to show that a single percentage is a population estimate, not an individual certainty. Treatment threshold example: 7.5% 10-year risk - Snyderman notes that at this threshold, 92.5% of people still will not have an event in 10 years. Long-horizon event rate in high ApoB group: 30% over 30 years - Used to make risk more meaningful for younger patients. High ApoB persistence: About 90-95% remain high - Snyderman says ApoB measured at age 35-40 is usually stable over time. Population share at evident high risk: About 20-25% - Used to argue that prevention can be targeted rather than universal at age 35. Risk model variance explained: About 20% - Michael Pencina’s work is cited to show current risk models capture only a minority of risk variance. Coronary calcium interpretation: Positive CAC is advanced disease - CAC is framed as a marker of established atherosclerosis rather than early disease. FH risk with genetic abnormality: 3-5 times higher risk - Snyderman cites a study suggesting genetically confirmed FH carries substantially higher risk than similar LDL-C without the mutation. Healthcare spending example: $7,000 per person per year (10 years ago in the U.S.) - Used to argue that adding ApoB testing would have negligible impact on overall healthcare costs.
Pivotal Quotes: "Atherosclerosis, it's a disease in the tissue and almost everything that lipid people talk about is in plasma." — Dr. Alan Snyderman: Explaining why pathology and natural history matter more than plasma-only thinking. "You cannot characterize any phenotype without putting an APOB in there." — Dr. Alan Snyderman: On why triglycerides and HDL-C alone are insufficient to define lipoprotein risk. "Stopping disease is perfect prevention. Treating disease is partial prevention and it has to be partial." — Dr. Alan Snyderman: Summarizing the rationale for early ApoB-based prevention rather than late intervention.
Implications: Listeners should think beyond LDL-C and short-term risk scores: ApoB better reflects causal exposure, earlier treatment may prevent disease rather than merely slow it, and CAC is only one piece of the puzzle. For medicine, the episode argues for guideline reform and broader ApoB adoption.
About Peter Attia Drive
Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.